Faculty Listing By Sites

Talmadge E. King Jr, MD
Medical Center Balance Sheet
Dean-SOM/VC-Medical Affairs

513 Parnassus Ave, Med Sci
San Francisco, CA 94122
415-476-2342

Dr. Talmadge E. King, Jr. was named dean of the UCSF School of Medicine and vice chancellor for medical affairs in May of 2015. He began his career at UCSF in 1997 as chief of Medical Services at Priscilla Chan and Mark Zuckerberg San Francisco General Hospital and Trauma Center. From 2006 to 2015, he served as chair of the UCSF Department of Medicine, the largest department in the school, with approximately 29 percent of the school's full-time faculty.


A physician-scientist, King's research has focused on inflammatory and immunologic lung injury. He is best known for his pioneering work in the management of the interstitial pneumonias, a scarring process that often leads to death. His bibliography comprises more than 300 publications and he has co-edited eight books, including the acclaimed reference book, "Interstitial Lung Disease," now in its fifth edition.


King graduated from Gustavus Adolphus College and earned his medical degree at Harvard Medical School, followed by a residency at Emory University Affiliated Hospitals in Atlanta, Ga. and a pulmonary fellowship at the University of Colorado Health Sciences Center in Denver.


He is a member of the Institute of Medicine of the National Academy of Sciences, American Academy of Arts and Sciences, Association of American Physicians, American Clinical and Climatological Association and the Fleischner Society. He is a master of the American College of Physicians and fellow of the American College of Chest Physicians. He won the 2007 Trudeau Medal, the highest honor of the American Thoracic Society.

Awards and Honors

2016   2016 APM Robert H. Williams, MD, Distinguished Chair of Medicine Award, Association of Professors of Medicine (APM), 2016
2012   Breathing for Life Award, Foundation of the American Thoracic Society, 2012
2012   Sesquicentennial Award, Gustavus Adolphus College, 2012
2011   Fellow, American Academy of Arts and Sciences, 2011
2010   Master, American College of Physicians, 2010
2008   Alumni Citation, Gustavus Alumni Association, Gustavus Adolphus College, 2008
2007   Trudeau Medal, American Thoracic Society, 2007
2004   Member, Institute of Medicine, National Academy of Sciences, 2004
2003   PAR Excellence Award, Public Advisory Roundtable of the American Thoracic Society, 2003
1998   Member, Association of American Physicians, 1998
1998   Elected honorary member, California Thoracic Society, 1998
1998   Member. Colorado Pulmonary Hall of Fame, Colorado Thoracic Society, American Lung Association of Colorado, 1998
1997   Member, The Fleischner Society, 1997
1993   Member, Western Association of Physicians, 1993
1992   James J. Waring Award For Outstanding Leadership in the Treatment of Lung Disease, American Lung Association of Colorado, 1992
1986   Fellow, American College of Physicians, 1986
1984   Fellow, American College of Chest Physicians, 1984
1980   First Decade Award for Early Achievement, Alumni Association, Gustavus Adolphus College, 1980
1970   Guild of St. Ansger Honor Society, Gustavus Adolphus College, 1970

Featured Videos

Related Web Sites

In the News

Recent Articles (117)

  1. Lucey CR, Navarro R, King TE. Lessons From an Educational Never Event. JAMA Intern Med. 2017 Oct 01; 177(10):1415-1416.

  2. Morisset J, Vittinghoff E, Elicker BM, Hu X, Le S, Ryu JH, Jones KD, Haemel A, Golden JA, Boin F, Ley B, Wolters PJ, King TE, Collard HR, Lee JS. Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model. Chest. 2017 11; 152(5):999-1007.

  3. Morisset J, Vittinghoff E, Lee BY, Tonelli R, Hu X, Elicker BM, Ryu JH, Jones KD, Cerri S, Manfredi A, Sebastiani M, Gross AJ, Ley B, Wolters PJ, King TE, Kim DS, Collard HR, Lee JS. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. Respir Med. 2017 Jun; 127:51-56.

  4. Brownell R, Moua T, Henry TS, Elicker BM, White D, Vittinghoff E, Jones KD, Urisman A, Aravena C, Johannson KA, Golden JA, King TE, Wolters PJ, Collard HR, Ley B. The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Thorax. 2017 May; 72(5):424-429.

  5. Sehgal NL, Neeman N, King TE. Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process. Acad Med. 2017 01; 92(1):78-82.

  6. Johannson KA, Elicker BM, Vittinghoff E, Assayag D, de Boer K, Golden JA, Jones KD, King TE, Koth LL, Lee JS, Ley B, Wolters PJ, Collard HR. A diagnostic model for chronic hypersensitivity pneumonitis. Thorax. 2016 10; 71(10):951-4.

  7. Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016 05; 71(5):429-35.

  8. Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res. 2016; 3(1):e000105.

  9. Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016 Jan; 47(1):243-53.

  10. Sverzellati N, Lynch DA, Hansell DM, Johkoh T, King TE, Travis WD. American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002. Radiographics. 2015 Nov-Dec; 35(7):1849-71.

  11. Assayag D, Kim EJ, Elicker BM, Jones KD, Golden JA, King TE, Koth LL, Shum AK, Wolters PJ, Collard HR, Lee JS. Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria. Respir Med. 2015 Oct; 109(10):1326-31.

  12. Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Noble PW. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Chest. 2015 Jul; 148(1):196-201.

  13. Assayag D, Vittinghoff E, Ryerson CJ, Cocconcelli E, Tonelli R, Hu X, Elicker BM, Golden JA, Jones KD, King TE, Koth LL, Lee JS, Ley B, Shum AK, Wolters PJ, Ryu JH, Collard HR. The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respir Med. 2015 Aug; 109(8):1058-62.

  14. Hansell DM, Goldin JG, King TE, Lynch DA, Richeldi L, Wells AU. CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society. Lancet Respir Med. 2015 Jun; 3(6):483-96.

  15. Nathan SD, du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir Med. 2015 Jul; 109(7):914-22.

  16. Collard HR, Bradford WZ, Cottin V, Flaherty KR, King TE, Koch GG, Kolb M, Martinez FJ, Montgomery B, Raghu G, Richeldi L, Rose D, Wells AU, Brown KK. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. Eur Respir J. 2015 Jul; 46(1):243-9.

  17. Durheim MT, Collard HR, Roberts RS, Brown KK, Flaherty KR, King TE, Palmer SM, Raghu G, Snyder LD, Anstrom KJ, Martinez FJ. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med. 2015 May; 3(5):388-96.

  18. Moodley Y, Corte T, Richeldi L, King TE. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. Respirology. 2015 Apr; 20(3):389-94.

  19. Costabel U, Albera C, Bradford WZ, Hormel P, King TE, Noble PW, Sahn SA, Valeyre D, du Bois RM. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20; 31(3):198-205.

  20. King TE, Noble PW, Bradford WZ. Treatments for idiopathic pulmonary fibrosis. N Engl J Med. 2014 08 21; 371(8):783-4.

  21. Flaherty KR, Fell C, Aubry MC, Brown K, Colby T, Costabel U, Franks TJ, Gross BH, Hansell DM, Kazerooni E, Kim DS, King TE, Kitachi M, Lynch D, Myers J, Nagai S, Nicholson AG, Poletti V, Raghu G, Selman M, Toews G, Travis W, Wells AU, Vassallo R, Martinez FJ. Smoking-related idiopathic interstitial pneumonia. Eur Respir J. 2014 Sep; 44(3):594-602.

  22. Ley B, Elicker BM, Hartman TE, Ryerson CJ, Vittinghoff E, Ryu JH, Lee JS, Jones KD, Richeldi L, King TE, Collard HR. Idiopathic pulmonary fibrosis: CT and risk of death. Radiology. 2014 Nov; 273(2):570-9.

  23. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2083-92.

  24. Valeyre D, Albera C, Bradford WZ, Costabel U, King TE, Leff JA, Noble PW, Sahn SA, du Bois RM. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology. 2014 Jul; 19(5):740-7.

  25. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2093-101.

  26. King TE, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med. 2014 Apr 01; 189(7):825-31.

  27. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE, Collard HR. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014 Apr; 145(4):723-728.

  28. Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn MR, Bradford W, Brown KK, Chapman HA, Collard HR, Cosgrove GP, Deterding R, Doyle R, Flaherty KR, Garcia CK, Hagood JS, Henke CA, Herzog E, Hogaboam CM, Horowitz JC, King TE, Loyd JE, Lawson WE, Marsh CB, Noble PW, Noth I, Sheppard D, Olsson J, Ortiz LA, O'Riordan TG, Oury TD, Raghu G, Roman J, Sime PJ, Sisson TH, Tschumperlin D, Violette SM, Weaver TE, Wells RG, White ES, Kaminski N, Martinez FJ, Wynn TA, Thannickal VJ, Eu JP. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med. 2014 Jan 15; 189(2):214-22.

  29. Assayag D, Lee JS, King TE. Rheumatoid arthritis associated interstitial lung disease: a review. Medicina (B Aires). 2014; 74(2):158-65.

  30. Assayag D, Lubin M, Lee JS, King TE, Collard HR, Ryerson CJ. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology. 2014 May; 19(4):493-500.

  31. Swigris JJ, Streiner DL, Brown KK, Belkin A, Green KE, Wamboldt FS. Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. Respir Med. 2014 Jan; 108(1):181-8.

  32. du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2014 May; 43(5):1421-9.

  33. Assayag D, Elicker BM, Urbania TH, Colby TV, Kang BH, Ryu JH, King TE, Collard HR, Kim DS, Lee JS. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology. 2014 Feb; 270(2):583-8.

  34. Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013 Sep 15; 188(6):733-48.

  35. Mooney JJ, Elicker BM, Urbania TH, Agarwal MR, Ryerson CJ, Nguyen MLT, Woodruff PG, Jones KD, Collard HR, King TE, Koth LL. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Chest. 2013 Aug; 144(2):586-592.

  36. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013 Jul 13; 14:73.

  37. Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, Jones KD, King TE, Ryu J, Collard HR. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013 Jul; 144(1):234-240.

  38. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013 Jul; 1(5):369-76.

  39. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2013 Jun 01; 187(11):1272.

  40. Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, Anstrom KJ, Martinez FJ. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest. 2013 Jun; 143(6):1699-1708.

  41. Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE, Wolters PJ, Collard HR. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013 Sep; 42(3):750-7.

  42. Lee JS, Kim EJ, Lynch KL, Elicker B, Ryerson CJ, Katsumoto TR, Shum AK, Wolters PJ, Cerri S, Richeldi L, Jones KD, King TE, Collard HR. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med. 2013 Feb; 107(2):249-55.

  43. Selman M, Pardo A, King TE. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012 Aug 15; 186(4):314-24.

  44. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012 May 24; 366(21):1968-77.

  45. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012 May 15; 156(10):684-91.

  46. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012 Jul 01; 186(1):88-95.

  47. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012 May 15; 185(10):1044-8.

  48. Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE, Ryu JH, Collard HR. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012 May; 67(5):407-11.

  49. King TE, Collard HR, Richeldi L. Interstitial lung diseases. Preface. Clin Chest Med. 2012 Mar; 33(1):xiii.

  50. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011 Dec 15; 184(12):1382-9.

  51. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Aug 15; 184(4):459-66.

  52. King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011 Dec 03; 378(9807):1949-61.

  53. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE, Collard HR. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Dec 15; 184(12):1390-4.

  54. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011 May 21; 377(9779):1760-9.

  55. King TE, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Jul 01; 184(1):92-9.

  56. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15; 183(6):788-824.

  57. King TE. Smoking and subclinical interstitial lung disease. N Engl J Med. 2011 Mar 10; 364(10):968-70.

  58. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011 May 01; 183(9):1231-7.

  59. Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Feb 15; 183(4):431-40.

  60. Castriotta RJ, Eldadah BA, Foster WM, Halter JB, Hazzard WR, Kiley JP, King TE, Horne FM, Nayfield SG, Reynolds HY, Schmader KE, Toews GB, High KP. Workshop on idiopathic pulmonary fibrosis in older adults. Chest. 2010 Sep; 138(3):693-703.

  61. Arjomandi M, Seward J, Gotway MB, Nishimura S, Fulton GP, Thundiyil J, King TE, Harber P, Balmes JR. Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility. J Occup Environ Med. 2010 Jun; 52(6):647-52.

  62. Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, Ishizaka A, Jones KD, King TE, Matthay MA, Kim DS. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010 Jul; 299(1):L3-7.

  63. Lee JS, Collard HR, Raghu G, Sweet MP, Hays SR, Campos GM, Golden JA, King TE. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med. 2010 Apr; 123(4):304-11.

  64. Kinder BW, Shariat C, Collard HR, Koth LL, Wolters PJ, Golden JA, Panos RJ, King TE. Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. Lung. 2010 Apr; 188(2):143-9.

  65. Levinson W, King TE, Goldman L, Goroll AH, Kessler B. Clinical decisions. American Board of Internal Medicine maintenance of certification program. N Engl J Med. 2010 Mar 11; 362(10):948-52.

  66. Swigris JJ, Wamboldt FS, Behr J, du Bois RM, King TE, Raghu G, Brown KK. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax. 2010 Feb; 65(2):173-7.

  67. Kim EJ, Collard HR, King TE. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009 Nov; 136(5):1397-1405.

  68. Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, Wamboldt FS. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med. 2010 Feb; 104(2):296-304.

  69. Buckley JD, Addrizzo-Harris DJ, Clay AS, Curtis JR, Kotloff RM, Lorin SM, Murin S, Sessler CN, Rogers PL, Rosen MJ, Spevetz A, King TE, Malhotra A, Parsons PE. Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine. Am J Respir Crit Care Med. 2009 Aug 15; 180(4):290-5.

  70. King TE, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, du Bois RM. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009 Jul 18; 374(9685):222-8.

  71. Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, King TE. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest. 2009 Jun; 135(6):1557-1563.

  72. King TE. Bosentan for idiopathic pulmonary fibrosis. Curr Opin Investig Drugs. 2008 Nov; 9(11):1171-9.

  73. Kinder BW, King TE. Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease. Am J Respir Crit Care Med. 2008 Jun 01; 177(11):1292-3; author reply 1293.

  74. Travis WD, Hunninghake G, King TE, Lynch DA, Colby TV, Galvin JR, Brown KK, Chung MP, Cordier JF, du Bois RM, Flaherty KR, Franks TJ, Hansell DM, Hartman TE, Kazerooni EA, Kim DS, Kitaichi M, Koyama T, Martinez FJ, Nagai S, Midthun DE, Müller NL, Nicholson AG, Raghu G, Selman M, Wells A. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med. 2008 Jun 15; 177(12):1338-47.

  75. Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest. 2008 Jan; 133(1):226-32.

  76. du Bois R, King TE. Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate. Thorax. 2007 Nov; 62(11):1008-12.

  77. King TE, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008 Jan 01; 177(1):75-81.

  78. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, King TE, Golden JA. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008 Jan; 102(1):150-5.

  79. Kinder BW, Freemer MM, King TE, Lum RF, Nititham J, Taylor K, Edberg JC, Bridges SL, Criswell LA. Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus. Arthritis Rheum. 2007 Aug; 56(8):2679-86.

  80. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Müller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007 Oct 01; 176(7):636-43.

  81. Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, Jones KD, King TE. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med. 2007 Oct 01; 176(7):691-7.

  82. Gotway MB, Freemer MM, King TE. Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias. Thorax. 2007 Jun; 62(6):546-53.

  83. Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, Gaxiola M, Pérez-Padilla R, Navarro C, Richards T, Dauber J, King TE, Pardo A, Kaminski N. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One. 2007 May 30; 2(5):e482.

  84. Collard HR, Loyd JE, King TE, Lancaster LH. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med. 2007 Sep; 101(9):2011-6.

  85. Portnoy J, Veraldi KL, Schwarz MI, Cool CD, Curran-Everett D, Cherniack RM, King TE, Brown KK. Respiratory bronchiolitis-interstitial lung disease: long-term outcome. Chest. 2007 Mar; 131(3):664-671.

  86. Calfee CS, Shah SJ, Wolters PJ, Saint S, King TE. Clinical problem-solving. Anchors away. N Engl J Med. 2007 Feb 01; 356(5):504-9.

  87. Flaherty KR, Andrei AC, King TE, Raghu G, Colby TV, Wells A, Bassily N, Brown K, du Bois R, Flint A, Gay SE, Gross BH, Kazerooni EA, Knapp R, Louvar E, Lynch D, Nicholson AG, Quick J, Thannickal VJ, Travis WD, Vyskocil J, Wadenstorer FA, Wilt J, Toews GB, Murray S, Martinez FJ. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med. 2007 May 15; 175(10):1054-60.

  88. Kinder BW, Collard HR, King TE. Anticoagulant therapy and idiopathic pulmonary fibrosis. Chest. 2006 Jul; 130(1):302-3.

  89. Kim DS, Collard HR, King TE. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006 Jun; 3(4):285-92.

  90. Walter N, Collard HR, King TE. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc. 2006 Jun; 3(4):330-8.

  91. Perez RL, Kimani AP, King TE, Aguayo SM, Roman J. Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis. Respiration. 2007; 74(3):297-303.

  92. Wesson DE, King TE, Todd RF, Torres EA, Hellmann DB, Flack JM, Dubose TD, Schuster VL. Achieving diversity in academic internal medicine: recommendations for leaders. Am J Med. 2006 Jan; 119(1):76-81.

  93. Shah NR, Noble P, Jackson RM, King TE, Nathan SD, Padilla M, Raghu G, Rhodes MB, Schwarz M, Tino G, Dubois RW. A critical assessment of treatment options for idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005 Oct; 22(3):167-74.

  94. Girod CE, King TE. COPD: a dust-induced disease? Chest. 2005 Oct; 128(4):3055-64.

  95. Lynch DA, Travis WD, Müller NL, Galvin JR, Hansell DM, Grenier PA, King TE. Idiopathic interstitial pneumonias: CT features. Radiology. 2005 Jul; 236(1):10-21.

  96. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE, Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005 Jun 21; 142(12 Pt 1):963-7.

  97. Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE, Bradford WZ, Schwartz DA, Richard Webb W. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005 Aug 15; 172(4):488-93.

  98. King TE. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med. 2005 Aug 01; 172(3):268-79.

  99. King TE, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz DA. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest. 2005 Jan; 127(1):171-7.

  100. King TE, Wheeler MB. Inequality in health care: unjust, inhumane, and unattended! Ann Intern Med. 2004 Nov 16; 141(10):815-7.

  101. Flaherty KR, King TE, Raghu G, Lynch JP, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, Murray S, Lama VN, Gay SE, Martinez FJ. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004 Oct 15; 170(8):904-10.

  102. Collard HR, Ryu JH, Douglas WW, Schwarz MI, Curran-Everett D, King TE, Brown KK. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest. 2004 Jun; 125(6):2169-74.

  103. Vourlekis JS, Schwarz MI, Cherniack RM, Curran-Everett D, Cool CD, Tuder RM, King TE, Brown KK. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med. 2004 May 15; 116(10):662-8.

  104. King TE, Dickinson TA, DuBose TD, Flack JM, Hellmann DB, Pamies RJ, Todd RF, Torres EA, Wesson DE. The case for diversity in academic internal medicine. Am J Med. 2004 Feb 15; 116(4):284-9.

  105. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004 Jan 08; 350(2):125-33.

  106. King TE. Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management. Trans Am Clin Climatol Assoc. 2004; 115:43-76; discussion 76-8.

  107. King TE. Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic. Semin Respir Crit Care Med. 2003 Oct; 24(5):567-76.

  108. Hunninghake GW, Lynch DA, Galvin JR, Gross BH, Müller N, Schwartz DA, King TE, Lynch JP, Hegele R, Waldron J, Colby TV, Hogg JC. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest. 2003 Oct; 124(4):1215-23.

  109. Morris DG, Jasmer RM, Huang L, Gotway MB, Nishimura S, King TE. Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence. Chest. 2003 Sep; 124(3):929-35.

  110. Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003 Sep 01; 168(5):538-42.

  111. Collard HR, King TE. Demystifying idiopathic interstitial pneumonia. Arch Intern Med. 2003 Jan 13; 163(1):17-29.

  112. Inoue Y, King TE, Barker E, Daniloff E, Newman LS. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2002 Sep 01; 166(5):765-73.

  113. Crystal RG, Bitterman PB, Mossman B, Schwarz MI, Sheppard D, Almasy L, Chapman HA, Friedman SL, King TE, Leinwand LA, Liotta L, Martin GR, Schwartz DA, Schultz GS, Wagner CR, Musson RA. Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med. 2002 Jul 15; 166(2):236-46.

  114. King TE. Nonspecific interstitial pneumonia and systemic sclerosis. Am J Respir Crit Care Med. 2002 Jun 15; 165(12):1578-9.

  115. King TE. Racial disparities in clinical trials. N Engl J Med. 2002 May 02; 346(18):1400-2.

  116. Vourlekis JS, Schwarz MI, Cool CD, Tuder RM, King TE, Brown KK. Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis. Am J Med. 2002 Apr 15; 112(6):490-3.

  117. Park JS, Brown KK, Tuder RM, Hale VA, King TE, Lynch DA. Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation. J Comput Assist Tomogr. 2002 Jan-Feb; 26(1):13-20.

  Select data provided by UCSF Profiles, powered by CTSI at UCSF. Learn more about the data source.